Welcome to our dedicated page for Cvrx SEC filings (Ticker: CVRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CVRx, Inc. filings document a Nasdaq-listed medical device company commercializing Barostim neuromodulation therapy for cardiovascular disease. Its Form 8-K reports record financial results releases, preliminary operating updates, material agreements, equity offering arrangements, amendments to its loan and security agreement, and executive compensation actions tied to performance stock units.
Proxy filings describe annual meeting matters, director elections, auditor ratification, board structure and stockholder voting procedures. The company’s SEC record also identifies its common stock, emerging growth company status, governance disclosures and capital-structure matters associated with debt and at-the-market equity financing.
CVRx, Inc. director Kirk G. Nielsen reported routine equity awards. He received 8,720 shares of common stock as a grant at $0.00 per share and a stock option for 11,182 shares of common stock at an exercise price of $5.43 per share, expiring on June 1, 2036. The option vests on the earlier of June 1, 2027 or the company’s 2027 annual stockholders’ meeting. The filing also shows 1,910,134 common shares held indirectly through Vensana Capital I, L.P., where Nielsen shares voting and dispositive power but disclaims beneficial ownership beyond his pecuniary interest.
CVRx, Inc. director Mudit K. Jain reported equity compensation grants. He received 8,720 shares of Common Stock at no cost, bringing his direct holdings to 14,370 shares. He was also granted a stock option for 11,182 shares at an exercise price of $5.43 per share, expiring on June 1, 2036. The option vests on the earlier of June 1, 2027 or the company’s 2027 annual stockholder meeting. Separately, 980,183 shares are held indirectly by Treo Ventures I, L.P., where Jain is the general partner and shares voting and dispositive power, while disclaiming beneficial ownership beyond his pecuniary interest.
CVRx, Inc. director Joseph P. Slattery reported compensation-related equity grants. He received 8,720 shares of Common Stock at no cost and a stock option for 11,182 shares with an exercise price of $5.43 per share, expiring on June 1, 2036. The option vests on the earlier of June 1, 2027 or the company’s 2027 annual meeting of stockholders. After these grants, Slattery directly holds 39,365 Common shares. These are awards, not open-market purchases or sales.
CVRx, Inc. director Mitch C. Hill received equity compensation in the form of common shares and stock options. He was granted 8,720 shares of Common Stock at no cost, leaving him with 8,720 common shares held directly after the award. He also received a stock option for 11,182 shares of Common Stock at an exercise price of $5.43 per share, expiring on June 1, 2036. According to the footnote, this award vests on the earlier of June 1, 2027 or the company’s 2027 annual meeting of stockholders, indicating a long-term, service-based incentive rather than an open-market purchase or sale.
CVRx, Inc. director Kevin J. Ballinger reported receiving equity compensation consisting of common shares and stock options. He was granted 8,720 shares of Common Stock at no purchase price, bringing his direct common share holdings to 8,720 shares.
He was also granted a stock option for 11,182 shares of Common Stock at an exercise price of $5.43 per share, expiring on June 1, 2036. According to the footnote, this award vests on the earlier of June 1, 2027 or the company’s 2027 annual meeting of stockholders.
CVRx, Inc. director Martha Shadan reported equity awards that increase her stake in the company. She received 8,720 shares of Common Stock as a stock grant at no cost, bringing her direct Common Stock holdings to 8,720 shares.
She was also granted stock options for 11,182 shares of Common Stock at an exercise price of $5.43 per share, expiring on June 1, 2036. According to the footnote, these options vest on the earlier of June 1, 2027 or the company’s 2027 annual meeting of stockholders. These compensation-related awards are not open-market purchases or sales.
A director of CVRx, Inc. received equity awards consisting of 29,005 shares of Common Stock and stock options covering 36,252 shares on June 1, 2026 as compensation.
The options have an exercise price of $5.43 per share, are exercisable for 36,252 shares of Common Stock, and expire on June 1, 2036. According to the vesting terms, one-third of the shares subject to these awards vest on each annual anniversary of the grant date. Following these awards, the director directly holds 29,005 shares of Common Stock and options on 36,252 shares.
CVRx, Inc. director Michael D. Dale filed a Form 3, which is an initial statement of beneficial ownership for company insiders. The filing lists him as a director and does not report any buy, sell, or other transactions in CVRx stock at this time.
CVRx, Inc. reported the results of its 2026 annual meeting of stockholders held on June 1, 2026. Stockholders elected three Class II directors — Michael Dale, Kevin Hykes, and Joseph Slattery — to serve until the 2029 annual meeting and until their successors are duly elected and qualified. Dale received 13,261,467 votes for and 24,036 withheld, Hykes received 12,040,949 for and 1,244,554 withheld, and Slattery received 11,938,599 for and 1,346,904 withheld, with 10,153,679 broker non-votes on each nominee.
Stockholders also ratified the appointment of Grant Thornton LLP as CVRx’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The auditor ratification received 21,150,201 votes for, 2,275,126 against, and 13,855 abstentions, indicating strong support for continuing with Grant Thornton LLP.
CVRx, Inc. reported first-quarter 2026 revenue of $14.8 million, up 20% from $12.3 million a year earlier, driven mainly by U.S. heart failure sales. U.S. revenue rose to $13.7 million as implanting centers and sales territories expanded, while European revenue was roughly flat.
Gross margin improved to 87% from 84% as manufacturing efficiencies lowered cost per unit. Operating expenses increased modestly, and the company recorded a net loss of $13.1 million, slightly better than the prior-year loss. Cash and cash equivalents were $72.3 million, and term loan borrowings rose to $60.0 million after a January 2026 amendment expanded the facility to $100.0 million and extended maturity to 2031. Management expects continued operating losses as it invests in commercialization of its Barostim neuromodulation device.